Published in Hepatitis Weekly, March 8th, 2004
The landmark APRICOT (AIDS Pegasys Ribavirin international co-infection trial) study showed 40% of patients treated with Pegasys (peginterferon alfa-2a), the most prescribed chronic hepatitis C treatment in the U.S., and Copegus (ribavirin), achieved a sustained virological response. Sustained virological response refers to a patient's continued undetectable hepatitis C virus levels in the blood 24 weeks after finishing a course...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.